Cardiff Oncology (CRDF)CFO bought ~$12K

~$12K

Approx. value · 2,400 sh @ $5.00

68K

Holds after · shares reported

Traded

Dec 18, 2024

Filed

Dec 18, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 11, 2024Insider · 1 personInsiders: 2 purchases (~$940K)
2. Dec 12, 2024InsiderDirector purchased ~$34K of CRDF shares in the open market
3. Dec 16, 2024InsiderCFO purchased ~$9.8K of CRDF shares in the open market
4. Dec 17, 2024InsiderCFO purchased ~$15K of CRDF shares in the open market
5. Dec 18, 2024 · this disclosureInsiderCFO purchased ~$12K of CRDF shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cardiff Oncology

For Cardiff Oncology, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CRDF page.

Other recent filings by James E. Levine, Chief Financial Officer

• SEC Form 4 at Cardiff Oncology (CRDF)Dec 18, 2024
• SEC Form 4 at Cardiff Oncology (CRDF)Dec 18, 2024

The full history of James E. Levine, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cardiff Oncology

• SEC Form 4Jul 16, 2026
• SEC Form 4Jul 16, 2026
• SEC Form 4Jun 22, 2026
• SEC Form 4Jun 22, 2026
• SEC Form 4Jul 31, 2025
• SEC Form 4Jul 31, 2025

Everything OQRO holds on this company is on its CRDF page.